ImClone Systems, the $3bn (€2.4bn) US biopharmaceutical company, has hired Lazard for the first time to conduct a strategic review that could include a merger or sale.

The Lazard managing directors working on the deal are Kenneth Jacobs, Jason Bernhard and Stephen Sands.